{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:21:35Z","timestamp":1791181295682,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[1989,10,1]],"date-time":"1989-10-01T00:00:00Z","timestamp":623203200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[1989,10]]},"DOI":"10.1007\/bf00442817","type":"journal-article","created":{"date-parts":[[2004,11,12]],"date-time":"2004-11-12T00:29:25Z","timestamp":1100219365000},"page":"248-251","source":"Crossref","is-referenced-by-count":97,"title":["Lack of effects of 5HT3 receptor antagonists in the social interaction and elevated plus-maze tests of anxiety in the rat"],"prefix":"10.1007","volume":"99","author":[{"given":"Sandra E.","family":"File","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda L.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"CR1","first-page":"9","volume":"89","author":"HA Baldwin","year":"1986","unstructured":"Baldwin HA, File SE (1986) The elevated plus-maze test of anxiety: further behavioural validation. Psychopharmacology 89:S9","journal-title":"Psychopharmacology"},{"key":"CR2","unstructured":"Brittain RT, Butler A, Coates IH, Fortune DH, Hagan R, Hill JM, Ireland SJ, Jack D, Jordan CC, Oxford A, Straughan DW, Tyers MB (1987) GR38032F, a novel selective 5HT3 receptor antagonist. Br J Pharmacol 90:87P"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.2042-7158.1988.tb05254.x","volume":"40","author":"B Costall","year":"1988","unstructured":"Costall B, Domeney AM, Gerrard PA, Kelly ME, Naylor RJ (1988) Zacopride: anxiolytic profile in rodent and primate models of anxiety. J Pharm Pharmacol 40:302?305","journal-title":"J Pharm Pharmacol"},{"key":"CR4","unstructured":"Donatsch P, Engel G, Richardson BP, Stadler P (1984) ICS 205-930: a highly selective and potent antagonist at peripheral neuronal 5-hydroxytryptamine (5-HT) receptors. Br J Pharmacol 81:34P"},{"key":"CR5","unstructured":"Fake CS, King FD, Sanger GJ (1987) BRL 43694: a potential novel 5-HT3 antagonist. Br J Pharmacol 91:335P"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/0028-3908(87)90065-7","volume":"26","author":"SE File","year":"1987","unstructured":"File SE (1987) The contribution of behavioural studies to the neuropharmacology of anxiety. Neuropharmacology 26:877?886","journal-title":"Neuropharmacology"},{"key":"CR7","first-page":"151","volume-title":"Animal models of psychiatric disorders, vol 1","author":"SE File","year":"1988","unstructured":"File SE (1988) How good is social interaction as a test of anxiety? In: Simon P, Soubrie P, Widlocher D (eds) Animal models of psychiatric disorders, vol 1. Karger, Basel, pp 151?166"},{"key":"CR8","volume-title":"Neurobiological aspects of panic disorder","author":"SE File","year":"1989","unstructured":"File SE (1989) Preclinical studies of the mechanisms of anxiety and its treatment. In: Ballenger JC (ed) Neurobiological aspects of panic disorder. Liss, New York (in press)"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1476-5381.1978.tb07001.x","volume":"62","author":"SE File","year":"1978","unstructured":"File SE, Hyde JRG (1978) Can social interaction be used to measure anxiety? Br J Pharmacol 62:19?24","journal-title":"Br J Pharmacol"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000118187","volume":"13","author":"AD Guy","year":"1985","unstructured":"Guy AD, Gardner CR (1985) Pharmacological characterisation of a modified social interaction model of anxiety in the rat. Neuropsychobiology 13:194?200","journal-title":"Neuropsychobiology"},{"key":"CR11","first-page":"31","volume-title":"Buspirone: a new introduction to the treatment of anxiety","author":"AL Johnston","year":"1988","unstructured":"Johnston AL, File SE (1988) Effects of ligands for specific 5HT receptor sub-types in two animals tests of anxiety. In: Lader M (ed) Buspirone: a new introduction to the treatment of anxiety. RSM Services Ltd, London, pp 31?41"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1476-5381.1988.tb11489.x","volume":"93","author":"BJ Jones","year":"1988","unstructured":"Jones BJ, Costall B, Domeney AM, Kelly ME, Naylor RJ, Oakley NR, Tyers MB (1988) The potential anxiolytic activity of GR38032F, a 5-HT3 receptor antagonist. Br J Pharmacol 93:985?993","journal-title":"Br J Pharmacol"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0165-0270(85)90031-7","volume":"14","author":"S Pellow","year":"1985","unstructured":"Pellow S, Chopin P, File SE, Briley M (1985) Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14:149?167","journal-title":"J Neurosci Methods"},{"key":"CR14","unstructured":"Piper D, Upton N, Thomas D, Nicholass J (1988) The effects of the 5-HT3 receptor antagonists BRL 43694 and GR 38032F in animal behavioural models of anxiety. Br J Pharmacol 94:314P"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.2042-7158.1988.tb05253.x","volume":"40","author":"WW Smith","year":"1988","unstructured":"Smith WW, Sancilio LF, Owera-Atepo JB, Naylor RJ, Lambert L (1988) Zacopride, a potent 5HT3 antagonist. J Pharm Pharmacol 40:301?302","journal-title":"J Pharm Pharmacol"},{"key":"CR16","first-page":"309","volume":"209","author":"RD Spealman","year":"1979","unstructured":"Spealman RD (1979) Comparison of drug effects on responding punished by pressurized air or electric shock delivery in squirrel monkeys: pentobarbital, chlordiazepoxide, d-amphetamine and cocaine. J Pharmacol Exp Ther 209:309?315","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00442817.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00442817\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00442817","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T20:38:40Z","timestamp":1554323920000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00442817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1989,10]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1989,10]]}},"alternative-id":["BF00442817"],"URL":"https:\/\/doi.org\/10.1007\/bf00442817","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[1989,10]]}}}